ABEO Abeona Therapeutics Inc

Price (delayed)

$0.17

Market cap

$24.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$7.86M

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The company's gross profit has shrunk by 67% YoY but it rose by 12% QoQ
The revenue has dropped by 67% year-on-year but it is up by 12% since the previous quarter
Abeona Therapeutics's net income has shrunk by 72% YoY and by 6% QoQ
Abeona Therapeutics's equity has shrunk by 67% YoY and by 39% QoQ

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
146.95M
Market cap
$24.98M
Enterprise value
$7.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.8
Price to sales (P/S)
7.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.35
Earnings
Revenue
$3.35M
EBIT
-$87.27M
EBITDA
-$82.78M
Free cash flow
-$69.58M
Per share
EPS
-$0.83
Free cash flow per share
-$0.48
Book value per share
$0.21
Revenue per share
$0.02
TBVPS
$0.38
Balance sheet
Total assets
$55.17M
Total liabilities
$23.73M
Debt
$9.1M
Equity
$31.44M
Working capital
$26.87M
Liquidity
Debt to equity
0.29
Current ratio
3.18
Quick ratio
3.02
Net debt/EBITDA
0.21
Margins
EBITDA margin
-2,474.1%
Gross margin
100%
Net margin
-2,681.6%
Operating margin
-2,864%
Efficiency
Return on assets
-93.4%
Return on equity
-145.5%
Return on invested capital
-304.1%
Return on capital employed
-203.7%
Return on sales
-2,608.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
-8.94%
1 week
6.25%
1 month
11.33%
1 year
-89.94%
YTD
-49.55%
QTD
-46.03%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$3.35M
Gross profit
$3.35M
Operating income
-$95.83M
Net income
-$89.73M
Gross margin
100%
Net margin
-2,681.6%
The operating income has plunged by 100% YoY and by 7% from the previous quarter
Abeona Therapeutics's net income has shrunk by 72% YoY and by 6% QoQ
The company's gross profit has shrunk by 67% YoY but it rose by 12% QoQ
The revenue has dropped by 67% year-on-year but it is up by 12% since the previous quarter

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
0.8
P/S
7.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.35
ABEO's EPS is down by 48% year-on-year but it is up by 3.5% since the previous quarter
The price to book (P/B) is 68% lower than the 5-year quarterly average of 2.5 and 43% lower than the last 4 quarters average of 1.4
Abeona Therapeutics's equity has shrunk by 67% YoY and by 39% QoQ
ABEO's P/S is 97% below its 5-year quarterly average of 235.4 and 61% below its last 4 quarters average of 19.1
The revenue has dropped by 67% year-on-year but it is up by 12% since the previous quarter

Efficiency

How efficient is Abeona Therapeutics business performance
The company's return on assets has shrunk by 176% YoY and by 29% QoQ
The company's return on invested capital fell by 40% QoQ
Abeona Therapeutics's return on equity has decreased by 33% QoQ
ABEO's ROS is up by 3.7% since the previous quarter

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets is 133% higher than its total liabilities
The company's total assets has shrunk by 61% YoY and by 31% QoQ
ABEO's total liabilities is down by 50% YoY and by 16% QoQ
Abeona Therapeutics's debt is 71% lower than its equity
Abeona Therapeutics's equity has shrunk by 67% YoY and by 39% QoQ
Abeona Therapeutics's debt to equity has surged by 61% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.